Case Report

Growing Teratoma Syndrome: A Rare Case Report and Review of the Literature

Nirmala Kampan,1 Trika Irianta,2 Arifuddin Djuana,2 Lim Pei Shan,1 Mohd Hashim Omar,1 and Ahmad Zailani Hatta Mohd Dali1

1 Obstetrics & Gynaecology, UKM Medical Centre, 56000 Cheras, Kuala Lumpur, Malaysia
2 Bagian Obstetri dan Ginekologi, Universitas Hasanuddin, Makassar 90245, Indonesia

Correspondence should be addressed to Nirmala Kampan, nirmala_k@hotmail.com

Received 3 January 2012; Accepted 16 February 2012

Academic Editors: B. A. Gbolade and J. Kumakiri

Copyright © 2012 Nirmala Kampan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Growing teratoma syndrome is rare and usually it occurs in the younger aged group. The use of chemotherapy following initial surgical resection will yield the diagnosis following tumour enlargement. Complete resection is usually curative and renders better prognosis.

1. Introduction

This report concerned a young patient with growing teratoma syndrome who required complete resection. Residual disease is the commonest suspicion following fertility conserving surgery for immature teratoma of ovary in a young woman. Administration of adjuvant chemotherapy is the usual course pathway for management of residual disease. An enlarging intraperitoneal mass despite course of chemotherapy is usually due to treatment failure but rarely may be as a result of growing teratoma syndrome. Complete resection is essential to prevent progression of tumour and is often curative, hence, it will render better prognosis than mature teratoma, are resistant to both chemotherapy and radiotherapy.

2. Case Presentation

A 17-year-old, nonparous girl presented with a one-month history of noticeable pelvic mass and was diagnosed to have a left ovarian tumour in 2007 with a raised serum CA-125 of 350 IU/L. Other tumour markers were not performed due to financial constraint. An intraoperative frozen section revealed immature teratoma and she underwent fertility sparing surgery. A staging laparotomy with left salpingo-oophorectomy, peritoneal cytology, pelvic lymph nodes sampling, and infracolic omentectomy was performed. Postoperative histology report revealed mature teratoma with focal area of immature teratoma of the left ovary. There was no malignant cell infiltration to the omentum or lymph nodes. Histology revealed immature teratoma grade I, FIGO stage 1a. Despite being advised for close surveillance, she defaulted followup after 6 months postoperative.

One year later, she presented with lower abdominal discomfort and resought medical advice. She developed radiological recurrence of pelvic mass with a raised serum CA-125 of 180 IU/L following which she completed 6 courses of systemic chemotherapy (carboplatin-paclitaxel). After chemotherapy, the tumour marker normalised (<35 IU/L) but the pelvic mass progressively increased in size. CT scan of the abdomen and pelvis revealed presence of bilateral large adnexal masses with infiltration into uterus and also possibly to the sigmoid colon. Growing teratoma syndrome was suspected. She underwent staging laparotomy and complete excision of the tumour. Full bilateral pelvic lymphadenectomy was done. Postoperative CT scan of the abdomen and pelvis showed no residual disease. Histology of excised mass revealed mature teratoma with no presence
of immature cells. The patient remained with no recurrence at the time of this report, which is 8 months after the second operation for GTS.

3. Discussion

Female ovarian growing teratoma syndrome (GTS), a rare encounter, is defined as an enlarging mature teratoma that arises during or following chemotherapy for a malignant germ cell tumor [1]. Five years later, it was renamed as “chemotherapeutic retroconversion.” The pathogenesis of this rare occurrence remained debatable. Selective elimination of the malignant cells by chemotherapeutic agents or differentiation of malignant cells into mature teratoma components following exposure to chemotherapeutic agents may be the two possible mechanisms responsible for development of GTS. As a result, often this is misinterpreted as chemoresistant tumour or recurrence. Complete resection is the key to a longer remission, however, the dilemma arises usually in younger women. Very few cases are reported on young Asian women with management still being debatable [2–7].

The youngest age reported in the literature is 5 years old [3]. The initial presenting symptoms are usually abdominal distension or discomfort. The initial histopathology is usually immature teratoma. As GTS mainly occurs in the young patient or with fertility concern, the initial surgery they usually underwent unilateral salpingo-oophorectomy. It is noted that the decision for lymphadenectomy is done not in all patient but it has been reported to have better local control and lowered the disease progression to GTS. The development of GTS had been reported as early as 3 months and in some cases, delayed till 8 years. Monitoring of response to chemotherapy is by serum tumour markers till low or normal levels [2–18]. This is one of the first reported growing teratoma from a completely excised stage 1a immature teratomas. The possible explanation for the appearance of growing teratoma syndrome may be as a result of micrometastases of the remaining immature teratoma cells within the peritoneal cavity. This may be as a result of intra-abdominal dissemination despite intact capsule which may occur spontaneously preoperatively.

Despite normalization of serum tumour markers during chemotherapy, the metastatic tumour grows and is usually identified on radiological imaging or ultrasonography. The feature usually reported in literature is soft pelvic tissue mass on CT scan or echogenic mass on ultrasound pelvis. Complete surgical excision is the treatment of choice with retroperitoneal pelvic and para-aortic lymph node dissection [2–12, 14–17, 19]. Most patient had laparotomy excision of tumour mass rather than by laparoscopy. This is probably due to adequacy concern of the selected method. Patients who had complete excision had longer disease-free interval up to 8 years with lowered recurrence episodes [6]. GTS varied in growth rate and is chemoresistant in most cases [2, 3, 11–13]. Early decision for complete resection had lowered morbidity in this patient as with delay, GTS that can grow rapidly may encase the blood vessels and other vital structures leading to pressure effect and potential risk of vascular thrombosis, ureteral obstruction, bowel obstruction, or colonic fistula [1–9, 12, 16–19]. The majority of mortality of GTS is related to postoperative complications [18]. Malignant transformation has been reported up to 3% of cases [16, 17]. The predetermining factors for development of GTS were reported as incomplete resection of primary tumour, presence of mature teratoma cells in the initial histology and no reduction in the size of tumour after chemotherapy [12].

GTS has an overall good prognosis with only a few reported deaths [4, 5, 18, 19]. The 5-year overall survival rate of patients who had underwent surgery following GTS is 89% [18]. However, close regular followup is essential as recurrence may ensue up to the 10 years after the initial diagnosis [6, 12]. GTS had been reported to have even occurred following a successful pregnancy [6].

Conflict of Interests

The authors declare that there are no conflict of interests.

References

[1] C. J. Logothetis, M. L. Samuels, A. Trindade, and D. E. Johnson, “The growing teratoma syndrome,” Cancer, vol. 50, no. 8, pp. 1629–1635, 1982.
[2] T.-Y. Hsieh, Y.-M. Cheng, F.-M. Chang, and C.-Y. Chou, “Growing teratoma syndrome: an Asian woman with immature teratoma of left ovary after chemotherapy,” Taiwanese Journal of Obstetrics and Gynecology, vol. 48, no. 2, pp. 186–189, 2009.
[3] T. Inaoka, K. Takahashi, T. Yamada et al., “The growing teratoma syndrome secondary to immature teratoma of the ovary,” European Radiology, vol. 13, no. 9, pp. 2115–2118, 2003.
[4] R. Hariprasad, L. Kumar, D. Janga, S. Kumar, and M. Vijayaraghavan, “Growing teratoma syndrome of ovary,” International Journal of Clinical Oncology, vol. 13, no. 1, pp. 83–87, 2008.
[5] K. Nimkin, P. Gupta, R. McCauley, B. F. Gilchrist, and M. S. Lessin, “The growing teratoma syndrome,” Pediatric Radiology, vol. 34, no. 3, pp. 259–262, 2004.
[6] H. Matsushita, K. Arai, M. Fukase, T. Takayanagi, and H. Ikarashi, “Growing teratoma syndrome of the ovary after fertility-sparing surgery and successful pregnancy,” Gynecologic and Obstetric Investigation, vol. 69, no. 4, pp. 221–223, 2010.
[7] W. Rekha, M. Amita, G. Sudeep, K. Shubhada, and T. Hemant, “Growing teratoma syndrome in germ cell tumour of the ovary: a case report,” Australian and New Zealand Journal of Obstetrics and Gynecology, vol. 45, no. 2, pp. 170–171, 2005.
[8] Y. Itani, M. Kawa, S. Toyoda, K. Yamagami, and K. Hiraoka, “Growing teratoma syndrome after chemotherapy for a mixed germ cell tumor of the ovary,” Journal of Obstetrics and Gynaecology Research, vol. 28, no. 3, pp. 166–171, 2002.
[9] A. R. Sengar and J. N. Kulkarni, “Growing teratoma syndrome in a post laparoscopic excision of ovarian immature teratoma,” Journal of Gynecologic Oncology, vol. 21, no. 2, pp. 129–131, 2010.
[10] G. Tzortzatos, A. Sioutas, and K. Schedvins, “Successful pregnancy after treatment for ovarian malignant teratoma with
growing teratoma syndrome,” *Fertility and Sterility*, vol. 91, no. 3, pp. 936.e1–936.e3, 2009.

[11] H. Tejura and A. O’Leary, “Growing teratoma syndrome after chemotherapy for germ cell tumour of the ovary,” *Journal of Obstetrics and Gynaecology*, vol. 25, no. 3, pp. 296–297, 2005.

[12] F. André, K. Fizazi, S. Culine et al., “The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients,” *European Journal of Cancer*, vol. 36, no. 11, pp. 1389–1394, 2000.

[13] K. S. Tonkin, G. J. S. Rustin, B. Wignall, F. Paradinas, and M. Bennett, “Successful treatment of patients in whom germ cell tumour masses enlarged on chemotherapy while their serum tumour markers decreased,” *European Journal of Cancer and Clinical Oncology*, vol. 25, no. 12, pp. 1739–1743, 1989.

[14] M. Mego, M. Recková, Z. Šyčová-Mila et al., “Bevacizumab in a growing teratoma syndrome. Case report,” *Annals of Oncology*, vol. 18, no. 5, pp. 962–963, 2007.

[15] B. Djordjevic, E. D. Euscher, and A. Malpica, “Growing teratoma syndrome of the ovary: review of literature and first report of a carcinoid tumor arising in a growing teratoma of the ovary,” *American Journal of Surgical Pathology*, vol. 31, no. 12, pp. 1913–1918, 2007.

[16] S. Kikawa, Y. Todo, S. Minobe, K. Yamashiro, H. Kato, and N. Sakuragi, “Growing teratoma syndrome of the Ovary: a case report with FDG-PET findings,” *Journal of Obstetrics and Gynaecology Research*, vol. 37, no. 7, pp. 926–932, 2011.

[17] H. Amsalem, M. Nadjari, D. Prus, N. Hiller, and A. Benshushan, “Growing teratoma syndrome vs. chemotherapeutic retroconversion: case report and review of the literature,” *Gynecologic Oncology*, vol. 92, no. 1, pp. 357–360, 2004.

[18] V. Gorbatiy, P. Spiess, and L. Pisters, “The growing teratoma syndrome: current review of the literature,” *Indian Journal of Urology*, vol. 25, no. 2, pp. 186–189, 2009.

[19] P. E. Spiess, W. Kassouf, G. A. Brown et al., “Surgical management of growing teratoma syndrome: The M. D. Anderson Cancer Center Experience,” *Journal of Urology*, vol. 177, no. 4, pp. 1330–1334, 2007.